Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215747 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
A Phase 3 study of Amyloidosis, sponsored by C.T. Development America.
- Completed
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
- 20
- Study locations
NCT01215747 is a Phase 3 study of Amyloidosis that has completed, run by C.T. Development America. The registered enrollment target is 261 participants, below the 1,120-participant average among 28 other Amyloidosis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01215747, a Phase 3 study of Amyloidosis, has completed, sponsored by C.T. Development America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA Amyloidosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KIACTA (eprodisate disodium)
Study Locations (20)
Other
- UZ Leuven - Leuven
- Al Hussain University Hospital - Cairo
- Tartu University Hospital - Tartu
- Helsingin yliopistollinen keskussairaala / Meilahti - Helsinki
- Hôpital Henri Mondor - Créteil
- Hôpital Claude Huriez - Lille
- Tbilisi Heart and Vascular Clinic Ltd - Tbilisi
- Universität Heidelberg - Heidelberg
- Regency Hospital - Kanpur
- Muljibhai Patel Urological Hospital - Nadiād
- Sir Ganga Ram Hospital - New Delhi
- Bnei Zion Medical Center - Haifa
- The Chaim Sheba Medical Center - Ramat Gan
- IRCCS Policlinico San Matteo - Pavia
- Pauls Stradins Clinical University Hospital - Riga
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Kaunas
- Vilnius University Hospital Santariskiu Klinikos - Vilnius
California
- Raffi Minasian MD a Medical Corporation - Glendale
Massachusetts
- Boston Medical Center - Boston
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215747
The ClinicalTrials.gov registry entry for NCT01215747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,120-participant average among 28 other Amyloidosis trials with a reported enrollment target (77% lower). The listed sponsor is C.T. Development America, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01215747 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01215747 about?
NCT01215747 is a clinical study titled "Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis". The primary purpose of this study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA Amyloidosis.
What is the current status of trial NCT01215747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2010-11. Estimated completion is 2016-03.
What conditions does trial NCT01215747 study?
This clinical trial studies the following conditions: Amyloidosis.
What interventions are being tested in trial NCT01215747?
The interventions under investigation include: Placebo (DRUG), KIACTA (eprodisate disodium) (DRUG).
Who is sponsoring clinical trial NCT01215747?
This trial is sponsored by C.T. Development America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01215747 being conducted?
This trial has 20 study locations across California, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
COMPLETED · Phase 3
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.